NO20065613L - 3-karbamoyl-2-pyridonderivat. - Google Patents

3-karbamoyl-2-pyridonderivat.

Info

Publication number
NO20065613L
NO20065613L NO20065613A NO20065613A NO20065613L NO 20065613 L NO20065613 L NO 20065613L NO 20065613 A NO20065613 A NO 20065613A NO 20065613 A NO20065613 A NO 20065613A NO 20065613 L NO20065613 L NO 20065613L
Authority
NO
Norway
Prior art keywords
hydrogen
alkyl
optionally substituted
itch
compounds
Prior art date
Application number
NO20065613A
Other languages
English (en)
Norwegian (no)
Inventor
Natsuki Ishizuka
Takashi Sasatani
Yoshilharu Hiramatsu
Masanao Inagaki
Masahide Odan
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NO20065613L publication Critical patent/NO20065613L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO20065613A 2004-10-28 2006-12-06 3-karbamoyl-2-pyridonderivat. NO20065613L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004313947 2004-10-28
JP2005159995 2005-05-31
PCT/JP2005/020248 WO2006046778A1 (ja) 2004-10-28 2005-10-28 ３－カルバモイル－２－ピリドン誘導体

Publications (1)

Publication Number Publication Date
NO20065613L true NO20065613L (no) 2007-05-29

Family

ID=36227998

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065613A NO20065613L (no) 2004-10-28 2006-12-06 3-karbamoyl-2-pyridonderivat.

Country Status (17)

Country Link
US (2) US8178681B2 (es)
EP (1) EP1806342B1 (es)
JP (4) JP4234176B2 (es)
KR (2) KR20080070878A (es)
CN (1) CN1993327B (es)
AU (2) AU2005297799B2 (es)
BR (1) BRPI0512985A (es)
CA (1) CA2572208C (es)
ES (1) ES2421143T3 (es)
IL (1) IL180331A (es)
IS (1) IS8578A (es)
MX (1) MX2007001320A (es)
NO (1) NO20065613L (es)
NZ (1) NZ551936A (es)
RU (1) RU2392271C2 (es)
TW (2) TW200843761A (es)
WO (1) WO2006046778A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE438624T1 (de) * 2000-12-28 2009-08-15 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
TW200843761A (en) * 2004-10-28 2008-11-16 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
JP2008544743A (ja) 2005-05-10 2008-12-11 インターミューン インコーポレイテッド ストレス活性化蛋白質キナーゼ系をモジュレートするためのピリドン誘導体
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
CN101541783B (zh) * 2006-06-30 2014-10-01 苏尼西斯制药有限公司 吡啶酮基pdk1抑制剂
AU2007292155B2 (en) 2006-09-05 2012-11-01 Kyowa Kirin Co., Ltd. Imidazole derivative
US8236841B2 (en) * 2006-09-13 2012-08-07 Kyowa Hakko Kirin Co., Ltd. Fused heterocycle derivative
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
MX2009006814A (es) * 2006-12-27 2009-07-02 Shionogi & Co Proceso para la produccion de un derivado de acido 2-piridon-3-carboxilico 1-sustituido.
US8410150B2 (en) 2007-03-09 2013-04-02 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8680282B2 (en) 2007-08-01 2014-03-25 University Health Network Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
BRPI0819258A2 (pt) * 2007-11-06 2017-05-02 Astrazeneca Ab alguns derivados de 2-pirazinona e seu uso como inibidores da elastase neutrófila
AU2008326784B2 (en) * 2007-11-20 2014-04-24 Merck Sharp & Dohme Corp. Non-nucleoside reverse transcriptase inhibitors
CN101215261B (zh) * 2008-01-03 2011-09-07 南京大学 合成2-氧代-3-吡啶甲酸酯及其衍生物的方法
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
EP2306828A4 (en) * 2008-06-25 2011-06-29 Glaxosmithkline Llc INHIBITORS OF PROLYL HYDROXYLASES
TW201006832A (en) 2008-07-15 2010-02-16 Novartis Ag Organic compounds
WO2010025087A1 (en) * 2008-08-25 2010-03-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
US8367836B2 (en) * 2009-04-27 2013-02-05 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US20120219596A1 (en) * 2009-07-30 2012-08-30 Wendelin Stark Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
JP5748947B2 (ja) * 2009-09-01 2015-07-15 公益財団法人相模中央化学研究所 ２−アシルアミノチアゾール誘導体及びその製造方法
WO2012110519A1 (de) * 2011-02-17 2012-08-23 Bayer Cropscience Ag Substituierte 3-(biphenyl-3-yl)-8,8-difluor-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-one zur therapie und halogensubstituierte spirocyclische ketoenole
CA2846659A1 (en) * 2011-08-29 2013-03-07 Ptc Therapeutics, Inc. Antibacterial compounds and methods for use
BR112014004515A2 (pt) 2011-08-29 2017-03-28 Ptc Therapeutics Inc "compostos antibacterianos, seu uso, composição farmacêutica e combinação terapêutica que os compreende"
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
WO2016045126A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
WO2016045128A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
WO2016045125A1 (en) 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CA3021660A1 (en) 2016-04-22 2017-10-26 Receptor Life Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
KR102253487B1 (ko) * 2017-01-03 2021-05-18 삼성전자주식회사 전선커버유닛을 포함하는 빌트인 냉장고

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8127998A (en) 1997-07-11 1999-02-08 Japan Tobacco Inc. Quinoline compounds and medicinal uses thereof
JP2000256323A (ja) * 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
MXPA01010993A (es) 1999-04-30 2002-07-22 Millennium Pharm Inc Compuestos inhibidores de la eca-2 y metodos para su utilizacion.
AU7315700A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
BR0112883A (pt) * 2000-08-01 2003-06-24 Ono Pharmaceutical Co Composto de derivado de 3,4-diidroisoquinolina e um agente farmacêutico compreendendo o mesmo como ingrediente ativo
US7420030B2 (en) * 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
WO2002039997A2 (en) 2000-11-01 2002-05-23 Millennium Pharmaceuticals, Inc. Ace-2 modulating compounds and use thereof
ATE438624T1 (de) * 2000-12-28 2009-08-15 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
GB0104268D0 (en) 2001-02-21 2001-04-11 Unilever Plc Antiperspirant or deodorant compositions
DE60228713D1 (de) 2001-07-18 2008-10-16 Unilever Nv Zusammensetzungen für die behandlung von haaren und/oder kopfhaut
TWI250023B (en) * 2001-10-22 2006-03-01 Santen Pharmaceutical Co Ltd Pharmaceutical composition for itch treating agent
CA2468794A1 (en) 2001-12-07 2003-06-19 Virginia Commonwealth University Treatment of neoplasia
WO2003061699A1 (fr) * 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedes pour affections allergiques
DE60329981D1 (de) * 2002-02-19 2009-12-24 Shionogi & Co Antipruriginosa
WO2004104000A1 (ja) 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
WO2004103974A1 (ja) 2003-05-23 2004-12-02 Japan Tobacco Inc. 置換２－オキソキノリン化合物およびその医薬用途
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
US7732442B2 (en) 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
GB0402355D0 (en) 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
US7897607B2 (en) 2004-04-07 2011-03-01 Takeda Pharmaceutical Company Limited Cyclic compounds
TW200843761A (en) * 2004-10-28 2008-11-16 Shionogi & Co 3-carbamoyl-2-pyridone derivatives

Also Published As

Publication number Publication date
IL180331A0 (en) 2007-07-04
KR20070046944A (ko) 2007-05-03
JPWO2006046778A1 (ja) 2008-05-22
JP4998952B2 (ja) 2012-08-15
EP1806342B1 (en) 2013-04-17
TW200619199A (en) 2006-06-16
IL180331A (en) 2011-12-29
CA2572208C (en) 2011-08-09
ES2421143T3 (es) 2013-08-29
US20120208813A1 (en) 2012-08-16
RU2006147307A (ru) 2008-07-10
US20080103139A1 (en) 2008-05-01
JP2008179635A (ja) 2008-08-07
JP4234184B2 (ja) 2009-03-04
KR20080070878A (ko) 2008-07-31
JP4234183B2 (ja) 2009-03-04
TWI360539B (en) 2012-03-21
CN1993327A (zh) 2007-07-04
MX2007001320A (es) 2007-04-02
WO2006046778A1 (ja) 2006-05-04
BRPI0512985A (pt) 2008-04-22
JP2008156366A (ja) 2008-07-10
RU2392271C2 (ru) 2010-06-20
EP1806342A4 (en) 2010-02-17
US8367666B2 (en) 2013-02-05
CN1993327B (zh) 2013-02-06
IS8578A (is) 2006-12-08
JP4234176B2 (ja) 2009-03-04
EP1806342A1 (en) 2007-07-11
AU2009202373B2 (en) 2011-01-06
TW200843761A (en) 2008-11-16
NZ551936A (en) 2010-07-30
CA2572208A1 (en) 2006-05-04
US8178681B2 (en) 2012-05-15
JP2008156365A (ja) 2008-07-10
KR100902798B1 (ko) 2009-06-12
AU2005297799A1 (en) 2006-05-04
AU2009202373A1 (en) 2009-07-02
AU2005297799B2 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
NO20065613L (no) 3-karbamoyl-2-pyridonderivat.
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
NO20073325L (no) Nye naftalenforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
WO2005080384A3 (en) Benzimidazole derivative and use as aii receptor antagonist
NO20065578L (no) Substituerte metylaryl eller heteroarylamidforbindelser
BRPI0612926B8 (pt) compostos fluorados de 4-(2-amino-1-hidroxietila)fenol como agonistas de receptores b2 adrenérgicos, composição farmacêutica, combinação e uso de um composto
RS52519B (en) SPIROCYCLIC COMPOUNDS WHICH ARE INHIBITORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
NO20055688L (no) Organiske forbindelser
UY30387A1 (es) Nuevos compuestos
WO2008101935A3 (fr) Nouveaux composés dérivés d'indole et compositions pharmaceutiques les contenant
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
MX2010001576A (es) Compuestos 3´sustituidos que tienen afinidad con el receptor 5-hidroxitriptamina 6 (5-ht6).
NO20072409L (no) Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser
ME00680B (me) Nova jedinjenja diozmetina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
NO20071314L (no) Peptidiske vasopressinreseptoragonister
MA33675B1 (fr) Composé indazole et pyrazolopyridine en tant qu'antagonistes du récepteur ccr1
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
MX2009008324A (es) Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6.
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
DE602005014629D1 (de) Pyrazolphenylderivate als ppar-aktivatoren
NO20071230L (no) Oksazolidinoner inneholdende oksindoler som antibakterielle midler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application